Minerva Neurosciences, Inc (NERV): Price and Financial Metrics
GET POWR RATINGS... FREE!
NERV Stock Price Chart Interactive Chart >
NERV Price/Volume Stats
|Current price||$0.35||52-week high||$3.14|
|Prev. close||$0.36||52-week low||$0.33|
|Day high||$0.40||Avg. volume||109,926|
|50-day MA||$0.64||Dividend yield||N/A|
|200-day MA||$1.05||Market Cap||14.97M|
Minerva Neurosciences, Inc (NERV) Company Bio
Minerva Neurosciences, Inc. focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company was founded in 2007 and is based in Waltham, Massachusetts.
Most Popular Stories View All
NERV Latest News Stream
|Loading, please wait...|
NERV Latest Social Stream
View Full NERV Social Stream
Latest NERV News From Around the Web
Below are the latest news stories about Minerva Neurosciences Inc that investors may wish to consider to help them evaluate NERV as an investment opportunity.
Minerva Neurosciences, Inc. (NASDAQ:NERV) Director David Kupfer sold 55,635 shares of the stock in a transaction dated Wednesday, December 1st. The shares were sold at an average price of $0.88, for a total transaction of $48,958.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through 
Zacks Investment Research upgraded shares of Minerva Neurosciences (NASDAQ:NERV) from a hold rating to a buy rating in a report released on Friday morning, Zacks.com reports. They currently have $1.00 target price on the biopharmaceutical companys stock. According to Zacks, Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and 
Minerva Neurosciences (NASDAQ:NERV) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a note issued to investors on Friday, Zacks.com reports. The brokerage currently has a $1.00 target price on the biopharmaceutical companys stock. Zacks Investment Researchs price objective indicates a potential upside of 7.99% from the companys current 
Zacks Investment Research cut shares of Minerva Neurosciences (NASDAQ:NERV) from a buy rating to a hold rating in a research report report published on Wednesday, Zacks.com reports. According to Zacks, Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central 
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
NERV Price Returns